



Symetis reaches key milestone – 1000 patients treated with ACURATE *neo*[™] aortic heart valve

Lausanne/Ecublens, Switzerland, September 21, 2015 – Symetis SA, a medical technology company ("Symetis"), announced today that less than a year after its commercial launch its state-of-the-art transcatheter aortic valve, ACURATE *neo*/TF, has been implanted in more than 1000 patients. Symetis's ACURATE TA system, launched in 2011, has achieved a number two position in its segment of the European TAVI market.

The 1000th procedure was carried out at the Ferrarotto Hospital of the University of Catania, Italy, on September 15, 2015. "With its stability during implantation, and the resulting predictability of success ACURATE TF has really exceeded our expectations," said Prof. Dr. Corrado Tamburino, Head of Cardiology of the Ferrarotto Hospital. "The ACURATE TF system scored high on all key parameters, such as procedural success, paravalvular leak, and pacemaker implant rate."

Prof. Dr. Helge Möllmann of the Kerckhoff Klinik in Bad Nauheim, Germany, concurred. "We have worked closely together with Symetis in the development of the ACURATE *neo*/TF system, which has resulted in an outstanding TAVI system with a very high procedural success rate of 98%, and low mortality. Excellent patient outcomes and ease of use are the hallmarks of ACURATE *neo*/TF."

"Together with our clinical partners and our growing field force we have been able to reach the 1000 patient mark for ACURATE *neo* TF in half the time it took us for ACURATE TA," said Jacques Essinger, CEO of Symetis. "The TAVI market is expected to grow to an estimated USD 3 billion worldwide in 2019, and as a pure-play TAVI company we believe we are well-positioned in this space."

TAVI, which is less invasive than open-heart surgery, is gaining increased acceptance in treating patients with severe aortic stenosis, who are considered high-risk for traditional open-heart surgery. The two main access routes in TAVI are through the femoral artery (transfemoral) and the apex or tip of the heart (transapical).

Symetis's ACURATE *neo*[™] valve has been developed and approved for transfemoral procedures, which constitute approximately 85% of all TAVI procedures in the European market according to BIBA MedTech Insights, TAVI report Q2 2015. It complements the Company's successful transapical system, ACURATE TA, which with a 21% market share has claimed a strong second place in the transapical segment of the European TAVI market. Together with Edwards Lifesciences (NYSE: EW) and Medtronic (NYSE: MDT), Symetis is the only company that provides TAVI valves for both TF and TA options for transcatheter aortic heart valve delivery.

About the ACURATE TAVI[™] product family

The Symetis transfemoral TAVI system consists of the ACURATE *neo*[™] Aortic Bioprosthesis and the ACURATE TF[™] Transfemoral Delivery System. The self-positioning bioprosthesis is composed of a porcine pericardial tissue valve sewn into a self-expanding nitinol stent covered with an anti-leak porcine pericardial skirt. Its transfemoral delivery system is designed for a simple 2-step deployment and stable positioning within the native annulus. The product is available in three sizes (S, M, L) to treat patients with aortic annulus diameters from 21mm to 27mm.

The Symetis transapical TAVI system consists of the ACURATE TA[™] Aortic Bioprosthesis and its Transapical Delivery System. The self-positioning bioprosthesis is composed of a noncoronary leaflet surgical quality porcine tissue valve sewn into a self-expanding nitinol stent covered with an anti-leak PET skirt. Its transapical delivery system is designed for quick, sheathless 2-step deployment and tactile positioning within the native annulus. The product is



available in three sizes (S, M, L) to treat patients with aortic annulus diameters from 21mm to 27mm.

About Symetis

Symetis SA is a leading Swiss medical technology company, focused on transcatheter aortic valve implantation (TAVI). Symetis' products, ACURATE TA™ and ACURATE neo/TF and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis believes that the ACURATE family of products offers superior performance characteristics and is well positioned to target the estimated USD 3 billion TAVI market in 2019. The Company generated revenues of CHF 17.9 million in 2014 and CHF 10.8 million in the first half of 2015. It is financed by leading European venture capital firms, including Endeavour Vision, Truffle Capital, Novartis Bioventures, Wellington Partners, Banexi Venture Partners, Aravis Venture, Vinci Capital, NBGI Ventures and BiomedInvest.

For more information visit www.symetis.com.

Media inquiries:

Hans Herklots
Head Investor Relations
Tel: +41 79 598 7149
hans.herklots@symetis.com

Christophe Lamps (Swiss media)
Dynamics Group
+41 79 476 2687
cla@dynamicsgroup.ch